You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
McKesson
Johnson and Johnson
Boehringer Ingelheim
McKinsey

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

Patent: 9,603,739

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,603,739
Title:Intraocular delivery devices and methods therefor
Abstract: Injection devices for delivering pharmaceutical compositions into the eye are described. Some devices include a resistance component for controllably deploying an injection needle through the eye wall. The resistance component may be disposed on the injector device, or on a portion of the injection device housing, or on a drug reservoir. Some devices may be removably attached to a drug reservoir, for example, through a luer connector. Other devices may comprise internal luer seal for securely connecting a drug conduit of the device to the luer cavity of a drug reservoir. Yet other devices may comprise a priming-enabling element to facilitate the drug priming of a shielded needle. Related methods and systems comprising the devices are also described.
Inventor(s): Lerner; Leonid E. (Corona Del Mar, CA)
Assignee: OcuJect, LLC (Newport Beach, CA)
Application Number:14/839,795
Patent Claims:see list of patent claims

Details for Patent 9,603,739

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial OcuJect, LLC (Newport Beach, CA) 2032-04-02 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial OcuJect, LLC (Newport Beach, CA) 2032-04-02 RX Orphan search
Genentech LUCENTIS ranibizumab INJECTABLE; INJECTION 125156 001 2006-06-30   Start Trial OcuJect, LLC (Newport Beach, CA) 2032-04-02 RX search
Regeneron Pharmaceuticals EYLEA aflibercept INJECTABLE; INJECTION 125387 001 2011-11-18   Start Trial OcuJect, LLC (Newport Beach, CA) 2032-04-02 RX search
Thrombogenics, Inc JETREA ocriplasmin INJECTABLE; INTRAVITREAL 125422 001 2012-10-17   Start Trial OcuJect, LLC (Newport Beach, CA) 2032-04-02 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Colorcon
Merck
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.